Eli Lilly: invests $5.3 billion in its Indiana site
This operation is designed to boost production capacity for active pharmaceutical ingredients (APIs) for Zepbound (tirzepatide) and Mounjaro (tirzepatide), offering greater capacity for treatments against obesity and type 2 diabetes.
The company has invested more than $16 billion since 2020 in new manufacturing facilities in the United States and Europe.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction